Clinical Trial: A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07760454) titled 'A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma' on Aug. 02.

Brief Summary: This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM). The study aims to evaluate the safety, tolerability, efficacy, cellular kinetics, and immunogenicity of CT0596.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Multiple Myeloma

Intervention: DRUG: CT0596

CAR-T cells

Recruitment Status: NOT_YET_RECRUITING

Sponsor: UCARsgen Biotech Limited

Published by HT Digital Content Services with permission from Heal...